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Abstract 
 
 
Purpose The purpose of the article is to examine the role of public procurement as a means to 
stimulate innovation among Small and Medium Sized Enterprises (SME’s). 
Design/methodology/approach The paper combines a narrative literature review with a 
multiple case study of six innovation projects.  
Findings The literature provides ambiguous support for the general claim that SME’s should 
be more innovative than larger firms. Even if SME’s can be innovative, this does not mean 
that all SME’s are. The case study findings suggest that few of the challenges innovating 
SME’s are facing would be ameliorated by developing public procurement of innovation 
policies specifically targeting SME promotion.  
Research limitations/implications The analysis of the literature remains on aggregate levels. 
The included firms worked with health tech innovation. 
Originality/value Unlike many studies and policy reports connecting ostensibly public 
procurement of innovation policies with SME promotion, this paper calls for a more critical 
view regarding policy development based on the SME construct.  
 
Keywords: SME involvement, public procurement, innovation 
 
1. Introduction 
 
This paper concerns the connection between small and medium-sized firms (SMEs) as 
suppliers of innovative technology and public health authorities’ utilisation of public 
procurement as an innovation-stimulating instrument. The interest in SME’s is justified 
simply by the fact that they are an important category in most economies. 99% of firms in the 
non-financial business sector in the EU28 are SME’s (European Union, 2014). SME’s are 
considered the “backbone of the European economy” as this category of firms contribute to 
more than half of European GDP (Wessel Thomasson et al., 2014). They are also a category 
generally associated with innovation, job creation, sustainability and other commendable 
features. Public procurement then, has since the beginning of the 2000s been assigned the role 
of an innovation policy instrument. Initially in the EU - and subsequently in many parts of the 
world - public procurers have been urged to adopt more innovation-friendly and innovation-
demanding practices in order to stimulate private sector innovation, ultimately to sustain 
competitive advantage.  
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It naturally follows that many countries have developed a policy interest for SME’s and also a 
concern for involvement of SME’s in public procurement (Zheng, Walker and Harland, 2006; 
Loader, 2013). Facilitating SME access to public procurement is also mentioned in the 
European action plan for implementing the European Strategy for the Baltic Sea Region 
(European Commission, 2010a). The new EU Procurement Directives have also been revised 
with the ambition to facilitate “…in particular the participation of small and medium-sized 
enterprises (SMEs) in public procurement” (OJ L, 2014). 
 
A closer look at the evidence presumably available for underpinning this policy interest 
renders, however, a somewhat ambiguous outcome, in particular when searching for academic 
justification for public procurement of innovation policies explicitly targeting SME’s. 
Freeman (2013, p. 9) notes that “it is far from obvious that SMEs as a group are in fact major 
contributors to economic growth.” Recently, procurement law experts concluded that “the 
time for wholesale review of SME policies is ripe” (Nicholas and Fruhmann, 2015, p. 351). 
The situation appears to resemble what Gibb (2000) noted one and a half decade ago, when 
looking back on SME research conducted up to that point. He argued that the accumulated 
knowledge included a number of myths or commonly held beliefs established among 
academics and policymakers, which led to the development of support activities that lacked 
rigorous underpinning.  
 
This paper examines a set of issues useful for furthering the discussion of public procurement 
policies as a means to stimulate SME’s as suppliers for public health tech innovation - an 
exercise that to some extent echoes Gibb’s observation. The generic research question 
addressed is formulated as follows: What are the justifications for developing public 
procurement of innovation policies for SME’s? The approach is post-positivist in the sense 
that the ambition is to be “more cautious concerning strong and one-sided interpretations and 
restrained regarding the too extensive (or obsessive) use of (quantitative) data and methods” 
(Adam, 2013, p. 5). The argument brought forward here draws on a narrative literature review 
and case studies conducted in the context of the HealthPort project, described in more detail 
in the paper. The ambition is to “pull many pieces of information together into a readable 
format” presenting “a broad perspective on a topic” and “provoke thought” which is 
characteristics for a narrative literature review (Green et al., 2006, p. 103).  
 
The paper begins with a brief introduction of the underlying principle of using public 
procurement as a means to stimulate innovation (section 2). Section 3 reviews literature that 
supports the general claim that different barriers inhibit SME involvement in public 
procurement. In an ideal world a natural subsequent step would be to establish to what extent 
public procurement of innovation with SME’s as suppliers actually occurs. This study has 
failed to find studies on SMEs which distinguish between procurement of regular goods and 
services and procurement where some kind of innovative activity actually takes place. 
Existing surveys tend to settle for establishing SME involvement in public procurement in 
general or by distinguishing by sectors, or sub-categories of firm size (micro, small and 
medium-sized) within the SME category. This means that firms typically not associated with 
innovation such as the local fast-food shop are bundled together in the same category as any 
university spin-off, high-tech companies. What would be needed for our purposes here are 
studies that distinguish between SME’s involvement in public procurement of off-the-shelf 
goods such as fuel, food or office supplies and public procurement from SME’s which renders 
innovation e.g. new energy systems, new products or services. Due to the lack of appropriate 
data, section 4 therefore settles to use an overview of the current SME involvement in public 
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procurement in general as a starting point for discussing the connection between public 
procurement of innovation and SME involvement.  
 
The other strategy adopted to overcome the data problem was to explore to what extent the 
general increase of SME involvement in public procurement would give reasons to expect 
increased innovation. Thus, section 5 reviews literature that considers to what extent SME’s 
are actually more innovative than larger firms and renders a rather inconclusive result: 
Generally there is no support for the claim that SME’s should be more innovative than larger 
firms. Section 6 reports from a study of six innovative SME’s located in the Baltic Sea Health 
region about their perception of barriers for the commercialisation of health tech innovations. 
Even if some participating firms did have some insights regarding the role of public 
procurement, other challenges such as barriers in relation to reaching the market, funding and 
complying with legal frameworks turned out more critical. Section 7 discusses the results and 
outlines some general conclusions. 
 
2. Public procurement and innovation 
 
Public	procurement	is	the	central	sourcing	mechanism	evoked	to	directly	secure	items	
needed	 for	 the	 delivery	 of	 public	 services	 (Thai	 and	 Grimm,	 2000).	 As	 such,	 it	 is	 not	
different	 from	any	other	 forms	of	 (private)	procurement	(Caldwell	and	Bakker,	2009).	
Similar	 to	what	would	 happen	 in	 a	 firm	 setting,	 the	 public	 procurer	 forms	 a	 supplier	
relationship	 to	satisfy	a	particular	need.	Most	public	procurement	projects	go	 through	
the	 following	 phases	 (van	 Weele,	 2005):	 a	 tactical	 function/initial	 purchasing	 stage	
where	 the	 procurer	 develops	 specifications,	 selects	 suppliers	 and	 issues	 a	 contract	
followed	 by	 an	 operational	 stage	 where	 the	 contract	 execution	 is	 monitored	 and	
evaluated,	 i.e.	 where	 the	 procured	 item	 is	 delivered.	 Differences	 are	 found	 in	 the	
institutional	set-up	in	which	public	procurement	occurs.	Public	procurement	is	affected	
by	 public	 policy	 and	 legislative	 packages	 on	 different	 levels	 (Thai,	 2009).	 Public	
procurement	 in	 EU	Member	 states	 is	 regulated	 by	 national	 procurement	 law	 in	 turn	
implementing	 the	 European	 Directives	 on	 Public	 procurement.	 Rules	 for	 public	
procurement	 are	 designed	 to	 prevent	 fraud,	maintain	 competition	 and	 thereby	 lower	
the	 prices	 public	 procurers	 have	 to	 pay	 (for	 elaboration	 of	 the	 similarities	 and	
differences	with	private	procurement	see	Bovis,	2007).	This	means	that	any	tender	call	
most	be	published	and	made	available	to	any	competitors;	award	and	selection	criteria	
must	be	 formulated	 in	advance.	Any	bidders	may	also	be	required	 to	substantiate	any	
required	competences	and	skills	as	well	as	economic	soundness.	
	
Through	the	policy	development	the	last	fifteen	years	the	role	of	public	procurement	as	
an	instrument	for	stimulating	innovation	has	been	increasingly	emphasized	and	is	today	
a	well-established	theme	in	the	EU	Horizon	2020	strategy,	as	well	as	in	policy	making	on	
the	global	level	(European	Commission,	2010b;	OECD,	2011;	UNOPS,	2014),	even	if	the	
degree	 of	 implementation	 of	 these	 policies	 varies	 between	 countries	 (Lember	 et	 al.,	
2014).	The	underlying	idea	is	to	encourage	public	procurers,	instead	of	procuring	items	
already	available	on	the	market,	to	stimulate	innovation	by,	developing	tender	calls	with	
specifications	 which	 effectually	 require	 --	 or	 at	 least	 allow	 --	 the	 submission	 of	
innovative	solutions.	Public	procurement	of	innovation	can	take	place	in	different	stages	
of	technological	maturity,	for	instance	as	applied	research,	feasibility	studies,	prototype	
development,	 but	 also	 as	 a	 vehicle	 for	 diffusion	 of	 technology	 which	 has	 reached	 a	
certain	 level	 of	maturity	 (Rothwell	 and	 Zegweld,	 1981);	 an	 observation	 justifying	 the	
recent	 development	 of	 pre-commercial	 procurement	 in	 the	 EU,	 where	 innovation	 is	
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achieved	 through	 procurement	 in	 phases	 with	 subsequently	 gained	 knowledge	 about	
the	 final	 solution	 ultimately	 leading	 to	 a	 commercial	 procurement	 (European	
Commission,	 2007).	 At	 the	 mature	 end	 of	 the	 spectrum	 belongs	 consolidating	
procurement,	 i.e.	 where	 standards	 or	 label	 schemes	 are	 used	 to	 disallow	 products	
underperforming	 in	 relation	 to	 e.g.	 energy	 efficiency	 or	 environmental	 requirements	
(Hommen	 and	 Rolfstam,	 2009).	 Sometimes	 the	 procured	 item	 qualifies	 as	 innovation	
only	in	the	sense	that	it	is	new	to	the	local	context	(Rolfstam	et	al.,	2011).	
	
Many	 authors	 have	 also	 corroborated	 the	 strategic	 role	 that	 different	 forms	 of	 public	
procurement	 can	 play	 as	 driver	 for	 innovation	 (e.g.	 Dalpé,	 DeBresson	 and	 Xiaoping,	
1992;	Gregersen,	1992;	Fridlund,	1999;	Palmberg,	2002;	Berggren	and	Laestadius,	2003;	
Rothwell,	1984;	Geroski,	1990;	Aschhoff	and	Sofka,	2009;	Eliasson,	2010;	Guerzoni	and	
Raiteri,	 2015).	 Concerning	 the	 health	 market,	 it	 represents	 in	 most	 OECD	 countries	
around	10%	of	national	gross	domestic	product	 in	which	the	public	sector	contributes	
with	70-80	%	of	the	total	spending	(OECD,	2013).	Public	health	authorities	are	therefore	
important	actors	in	the	health	innovation	system,	not	only	as	adopters	of	supplier	side	
innovation	 but	 also	 potentially	 as	 “intelligent”	 public	 procurers	 able	 to	 satisfy	 needs	
identified	 by	 patients	 and/	 or	 health-care	 professionals	 (Omachonu	 and	 Einspruch,	
2010).	 For	 suppliers	 of	 health	 tech	 innovation,	 this	 market	 becomes	 a	 locus	 for	
development	 of	 new	 knowledge,	 innovative	 products	 and	 subsequent	 competitive	
advantages.	 Herein	 prevails	 the	 strategic	 dimension	 which	 underscores	 the	 role	 of	
healthcare	 innovation	 as	 a	 means	 to	 generate	 competitive	 advantages,	 growth	 and	
employment.	In	this	perspective,	health	tech	suppliers	and	public	health	tech	procurers	
become	 a	 venue	 for	 user-producer	 interaction	 and	 interactive	 learning	 (von	 Hippel;	
Lundvall,	 1992),	 connectable	 to	 the	 general	 policy	 interest	 developed	 over	 the	 last	
decade	 which	 emphasises	 the	 role	 of	 public	 procurement	 as	 a	 means	 to	 stimulate	
innovation	 (Edler	 and	 Georghiou,	 2007;	 Uyarra	 and	 Flanagan,	 2010;	 Rolfstam,	 2013;	
Lember	et	al.,	2014).		
 
3. Barriers to SME involvement in public procurement 
 
Given the policy interest it is noteworthy that there appears to be many barriers that reduce 
the possibilities for SME’s participation in public procurement1. An extensive literature 
review by Loader (2013), provides a list of twenty-three barriers faced by SME’s organised 
into three main categories, barriers that relates to public policy; to the procurement process 
and those relating to SME’s specifically. In the first category are issues such as conflicting 
procurement objectives and cultural barriers such as risk-averse attitudes among public 
procurers. The second category includes uncertainty regarding the technical aspects of public 
procurement, such as lack of knowledge on procedures and challenges regarding the 
requirement to demonstrate a track record, or negative consequences of (too large) contract 
volumes. In the third category we find issues regarding to what extent SME’s have resources, 
skills and attitudes that would make them prone to participate in public procurement 
processes (ibid, 2013). Similar points have been made elsewhere: Karjalainen and 
Kemppainen (2008) found the lack of legal expertise and lack of administrative resources to 
be such a barrier. These authors also found that SME’s using electronic order and invoice 
systems would be more likely to get involved in state level procurement than those which don 
																																																								
1	It	is	not	the	purpose	here	to	evaluate	to	what	extent	any	barriers	affect	exclusively	SMEs.	Rolfstam	et	al.,	
2011	and	Eyarra	et	al.,	2014	suggest	barriers	to	involvement	in	public	procurement	can	be	perceived	also	
by	larger	firms.	
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not. Walker et al. (2008) mention an array of barriers related to SME’s and sustainable 
procurement. Some SME’s fail to adopt their market strategies for the public sector. SME’s 
might also be seen as inducing larger risks for the procurers.  
 
Based on stakeholder consultation, the European Commission listed an array of barriers for 
SME participation in public procurement (European Commission, 2008), which are consistent 
with findings in the academic literature (as cited above, see also Wessel Thomassen et al., 
2014). The findings suggest that due to lack of resources an array of sometimes related 
problems occur. SMEs experience difficulties in obtaining information about tender calls: in 
general they don’t have sufficient time to prepare bids and they lack knowledge about tender 
procedures. The cost of preparing the tenders was also seen as disproportionately high, giving 
advantages to larger enterprises with resources available to cope with the excessive 
administrative burden. Another issue of disproportionality concerned qualification levels, 
certification requirements; requirements for financial guarantees stated in tender calls, which 
were perceived as excessive. Tender calls with too big contracts and excessively long 
payment timeframes would also reduce SME proneness to participate in public tenders. A 
final type of barriers were related to international participation in public procurement, where 
discrimination against foreign tenderers and challenges in relation to finding cooperation 
partners abroad were seen as barriers. (European Commission, 2008.) For the European 
Commission the outcome of the consultation exercise was clear: “This leads to the conclusion 
that there is a need to develop a more SME-friendly approach to public procurement among 
contracting authorities by promoting the possibilities offered by the Public Procurement 
Directives to facilitate access by SMEs to public procurement opportunities, and by making 
known the relevant best practices in Member States” (European Commission, 2008, p. 5).  
 
It is not the purpose here to evaluate to what extent any barriers affect exclusively SMEs. The 
question remains, however, to what extent there are other ways of interpreting these findings 
and whether other policy implications can be deduced. Rolfstam et al., (2011) and Eyarra et 
al., (2014) find barriers to involvement in public procurement affecting also larger firms. 
Assuming one ascribes to the view that public procurement should be a disinterested process 
designed to safeguard that the most competitive supplier – i.e. the one best able to supply 
according to the specified need – is selected. Any firm or consortium of firms with adequate 
capacity regardless of size would then be considered a potential awardee of public contracts. 
Any other principle applied would lead to insufficient use of public money as well as 
aggravation among firms who realise they are excluded due to secondary policies, rather than 
judged inferior after objective application of award criteria. It is plausible that a subset of 
SME’s which submit bids without being awarded contracts are unsuccessful for the same 
reason big firms fail; that they in one way or another submit an inferior bid. The ambition 
should of course always be to remove unnecessary bureaucracy. One could then argue that a 
non- optimal situation might be when a certain category of firms becomes penalized for the 
sake of policy, forcing procurers to make less rational award decisions. In that sense there is a 
trade-off between rational competitive decisions and those affected by any secondary policies. 
It could be argued that if such deviation is allowed, policy makers should be aware of the 
implications. A central question in this debate is to what extent SME’s are actually 
disfavoured, a question which, as will be discussed in the subsequent section, is not easily 
answered in a straightforward manner.  
  
4. SME involvement 
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According to the official European definition are SME’s “enterprises which employ fewer 
than 250 persons and which have an annual turnover not exceeding EUR 50 million, and/or 
an annual balance sheet total not exceeding EUR 43 million” (European Commission, 2003, 
Article 2). Although definitions of SME that are used in different surveys might vary, the 
general outcome is that the SME share of the public procurement market is proportionally 
lower than larger firms (Nicholas and Fruhmann, 2014). Studying the UK context, Loader 
(2013) makes the same point; although a public contract may offer economic stability and 
prestige, relatively few SME’s bid for public contracts. The interest for SME participation in 
public procurement can be seen in recent comparative surveys conducted on the EU level, and 
also on national levels (Vincze, et al., 2010; Konkurrence- og Forbrugerstyrelsen, 2013; see 
also Loader, 2012 for a review of such studies in UK and the US). Common themes in these 
studies are attempts to establish to what extent SMEs are involved in bidding as well as 
winning public contracts. Often the findings are viewed in the light of the relative importance 
of SME’s for the total economy. For tender calls published in Tenders Electronic Daily (TED) 
database, i.e. those tender calls above the threshold values as stipulated by the European 
Directives on Public procurement, the proportion of SME’s directly awarded a contract was 
60% (years 2006-2008) which is similar to estimates for 2005 (61%) (Vincze, et al., 2010). 
Estimates for the years 2009-2011 suggest the SME involvement for public procurement 
contracts over the threshold values was 56%. Estimates provided by the Danish Competition 
and Consumer Agency on SME participation in Denmark suggests a similar level: Danish 
SME’s participates in 2/3 of Danish tender calls and win half of the tender calls. This should 
be compared with the private turnover, where SME’s contributes with 1/3 of the total turnover 
(Konkurrence- og Forbrugerstyrelsen, 2013).   
 
Recent estimates for Baltic Sea region countries reveal some country-specific differences 
(Table 1), which probably reflect the share of SME’s in relation to bigger firms in the specific 
country (European Commission, 2008). A general – and not surprising – tendency is that SME 
involvement is larger for contract values below threshold values2. If one looks at contracts 
with a value below the threshold values, the SME share appears to be quite substantial, 
reaching, in the extreme case of Latvia, 90% of the total contract value awarded to SME’s.  
 
Estimation of SMEs’ share of contract value awarded 
Country Above threshold % Below threshold (%)  
Germany  48  75  
Denmark  36  65  
Estonia  24  51  
Finland  29  57  
Lithuania  30  59  
Latvia  74  90  
Poland  25  53  
Sweden  19  44  
Total EU 27  29  58  
Table 1. Estimations of SME share of contract value awarded, years 2009-2011(Wessel Thomassen et 
al., 2014). 
 
The issue regarding SME involvement in public procurement triggers a set of sub-questions, 
such as what kind of involvement is envisaged and what effects are measured. It appears that 
the notion of involvement is frequently used as a synonym for being a contract owner, i.e. that 
the entity counted as ‘involved’ is also the contract owner, while involvement regulated 
																																																								
2	Threshold	values	are	those	values	which	determine	whether	a	contract	should	be	awarded	following	the	
EU	Directives.	Depending	on	what	is	procured	thresholds	range	from	EUR	134000	to	EUR	5186000.		
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through sub-contracting is disregarded. This might be problematic as awarding a contract to a 
large firm might still involve SME’s as sub-contractors as well as other suppliers not named 
as sub-contractors in the specific project. In other words, even if the contractor is a large firm, 
this may not necessarily exclude participation of SME’s, as SME’s may still be involved 
through other arrangements.  
 
Another issue of concern is whether there is such thing as an optimal SME share in public 
procurement. Any claim made from the data reviewed above suggesting that SME 
involvement in public procurement is too low seem to rely on the assumption that 
involvement in public procurement should mirror different firm categories’ importance in 
general: If 98% of firms are SME’s this should be reflected in SME involvement in public 
procurement. However, one could also argue that public procurement is not a “fair” process in 
that sense, but rather one that relies on rational decisions both in terms of how procurement 
projects are setup and how submitted bids are evaluated. The SME underrepresentation might 
be explained by for instance that certain contract require financial strength, experience and 
other capacities to larger extent held by larger firms. 
 
One central issue here is the relevance for promoting SME involvement with the purpose of 
rendering more innovation. A dedicated SME policy could be justified if evidence were 
available that demonstrates that SME involvement in public procurement would actually 
render more innovative solutions than public procurement conducted according to current 
practice. This reveals another complex issue which may not be easily solved: one could argue 
that public procurement organised in an adequate way to render or stimulate innovation would 
lead to the award of the contract to the most innovative bid, regardless of the size of the 
supplier. In that perspective the entire debate becomes pointless. The strategy chosen here is 
to address this issue on a generic level, i.e. try to establish whether or not SME’s are more 
innovative than larger firms. If it could be established that SME’s are more innovative than 
larger firms, stimulating SME involvement in public procurement could then be justified from 
an innovation policy rationale. However, as will be discussed below, this is not the case.  
 
5. SME and Innovation 
 
Concerning whether or not SME’s are more innovative than large firms, the evidence, in spite 
of what is sometimes claimed, is rather inconclusive. Symeonidis summarizes hypotheses 
proposed in the literature as to why larger firms would be more innovative: R&D typically 
involve large fixed costs, which can only be covered if sales are sufficiently large; There are 
scale and scope economies in the production of innovations (i.e. advantages more easily 
exploited by larger firms; large diversified firms are in a better position to exploit unforeseen 
innovations; large firms can undertake many projects at any one time and hence spread R&D 
risks; large firms have better access to external finance; firms with greater market power are 
better able to finance R&D from own inputs; firms with greater market power can more easily 
appropriate the returns from innovation and hence have better incentives to innovate 
(Symeonidis, 1996). The same author also summarizes counterarguments, i.e. why larger 
firms would be less efficient innovators. Less managerial control and bureaucracy associated 
with larger firms would decrease returns of scale; the absence of competition, i.e. in 
monopolistic situations, may lead to innovation inertia (ibid, 1996). In comparison, it is well 
established that incumbent firms typically tend to be less innovative in situations where there 
is a technology shift. In that sense appears size to be related to innovation inertia at some 
point. However, firm size per se appears not to be a central explanation variable in these 
situations. The underlying nature of the problems faced by incumbent firms in relation to 
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technology shifts appears not because they have ceased being innovative, but rather because 
they fail to be innovative in the disruptive technology (Christensen and Bower, 1996). 
 
The ambiguity prevails also if one considers quantitative research on the relation between 
firm size and innovation. In a survey conducted on UK firms’ innovative activities over the 
years 1945 to 1983 Pavitt et al. (1987) found the size distribution of innovative firms to be U-
shaped, i.e. suggesting smaller firms (between 500 and 1000 employees) and larger firms to 
be the most innovation intensive. Medium-sized firms (between 2000-999 employees) had 
below average innovation intensity. Variances were however found for specific sectors. In 
mining and defence for instance, most innovations where conducted by large firms (50000 
employees). Smaller firms were relatively more innovation intensive in the service, R&D and 
instrument sector (ibid, 1987).  Such sector differences were also reported by Acs and 
Audretsch drawing on US data recorded for 1982 (Acs and Audretsch, 1988).  In contrast to 
the study by Pavitt et al., (1987) Acs and Audretsch did however not find variation related to 
firm size. Instead, they found that “there does not appear to be a great difference in the 
"quality" and signify-cance of the innovations between large and small firms. However, the 
extent of innovative activity does not necessarily correspond to the market values of the 
innovations. It is conceivable that larger firms may tend to focus on innovations with a higher 
market value” (Acs and Audretsch, 1988, p. 681). Later, Cohen and Klepper found the 
relation between the size of the business unit and R&D effort stronger than the overall size of 
the (multi-product) firm. Also, in industries where innovations are saleable in disembodied 
form (through e.g. licensing) and/ or when there are better possibilities for growth due to 
innovation the importance of size is reduced (Cohen and Klepper, 1996). 
 
It appears then as if the general assertion that SME’s should be more innovative than larger 
firms is controversial, if viewed in the light of available literature. One could argue that this in 
turn reduces the justification for policies based on that general assertion.  Pavitt et al (1987) 
concluded that “our findings do not point to easy or obvious prescriptions for the policy-
maker. Given the high variance in the size distribution of innovating firms both within and 
between sectors, grand generalisations are often likely to be wrong, and grand policies often 
likely to be inappropriate. It is tempting to conclude that, under such circumstances, diversity 
and pluralism should be the only objectives of policy (Pavitt et al., 1987, p. 314)”.  
 
6. Public procurement and small innovative firms 
 
The points outlined above imply that the SME notion is a too crude construct if used as a 
device for targeting particularly innovative firms and also that a categorical prescription of 
SMEs as more innovative than larger firms fails to find underpinning in the literature. A 
tentative conclusion is then that a policy set-up to increase SME involvement in public 
procurement might not necessarily render more innovation and should in that sense be 
considered insufficient as an innovation policy. One unresolved question that remains 
concerns the role of public procurement for those SME’s which actually are innovative; it 
could be argued that the existence of these screening problems does not necessarily discredit 
the general idea of supporting SME’s as a means to stimulate innovation.  Maybe the problem 
would be settled by applying a more fine-tuned selection mechanism? Rather than examining 
any such options, the attention here turns towards inquiring about the conditions for a subset 
of innovative SME’s that would presumably be targets for procurement policies aiming to 
stimulate innovation; small innovative health tech firms.  
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The empirical material reported here was collected in the context of the Baltic Sea Health 
Region HealthPort project that ran from 2012 and 2014, and was co-funded by the European 
Development Fund. The overall aim with the project was to facilitate ‘business acceleration’ 
by providing support, training and bringing together innovative SMEs and health care 
organisations to strengthen the Baltic Sea Region health economy. One topic addressed by the 
project concerned how public procurement could facilitate SME access to the health care 
market. This was an intervening project where participating firms were offered a support 
scheme consisting of EUR 10.000 to be spent on activities aimed at facilitating the 
commercialisation of the respective potential innovations each firm had submitted to the 
project. 
 
6.1 Case selection and method 
  
The selected firms were treated as individual cases following a case study methodology (Yin, 
1994).  Before proceeding to the data collection stage a case study protocol was developed. 
The case study protocol summarized important aspects of the project, such as purpose, 
practical procedures and interview questions. As data were to be collected by a team of 
investigators, the case study protocol filled two purposes: to provide a guide for the data 
collection and to maintain reliability. Prior to data collection, a workshop was held with the 
case study team, where the case study protocol was discussed. The workshop was set up to 
establish a mutual understanding of the purpose with the project and procedures to follow 
throughout the data collection stage. 
 
The principle selection criteria applied were as follows: a. Selected candidates were either in 
project phase (i.e. not incorporated/ established as a firm) or SMEs in the life-science sector; 
b. They were involved in product innovation in cooperation with hospitals; c. willing to 
present their case, as well as interact with the HealthPort project. Other selection criteria came 
directly from the specific set-up of the HealthPort project. The ambition was to achieve 
technological variance, i.e. to select firms engaged in different technology areas. Another 
issue concerned the time-line of the projects. Cases were selected based on the probability of 
measuring progress during the study period. Further criteria concerned to what extent the 
selected firms would benefit from the support offered by the HealthPort project. A final 
criteria concerned the judgement of the potential for the BSR Bioregion and to what extent 
support to the candidate would contribute to the development of a better health care market in 
the BSR Bioregion. 
 
For each case two main events of data collection and interaction were organised. All initial 
meetings where conducted as physical meetings. In four of the cases the second meetings 
were conducted either as telephone meetings or video conference (SKYPE, Teamviewer). The 
meetings were recorded and transcribed. Summaries of the interviews were sent out to 
respondents to allow for comments and corrections. Additional communication occurred 
through email and telephone over the project duration. The purpose with the first meeting was 
to collect data as specified in the case study protocol and identify and agree on needs to be 
supported by the HealthPort project. The main purpose of the second meeting was to evaluate 
the effects of activities supported by the HealthPort project. The time between the first 
meeting and second meeting was 4-7 months (Table 2).		
 
Case 
no. 
Initial meeting (date, type) Evaluation meeting (date, type) 
1 4 April visit 23 August visit 
2 19 April visit 27 August Teamviewer conference 
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3 30 January 2013 visit 26 September Skype conference 
4 1 February 2013 visit 13 August Skype conference 
5 11 April 2013 visit 27 August 2013 skype conference 
6 20 February 2013 visit 26 August 2013 visit 
Table 2. Main events of data collection in the six cases 
 
6.2. Case study findings 
 
Included in the cases were firms established or about to be established in the Baltic Sea area. 
Included entities were registered in Estonia, Denmark (two cases), Finland, Germany and 
Sweden. Technologies represented were IT/ software development, telemedicine, health tech 
appliances and drugs. Each case and their respective innovations are displayed in Table 3 and 
described above. 
 
Case 
no. 
Innovation Benefit 
1 Cloud-based IT system for patient 
management 
Enable better services for patients, faster and adequate 
decisions, long term analysis. 
2 Personalized diabetes treatment system  Due to increased control making patients able to live 
more ‘normal’ lives. Reduce number of emergency 
responses due to increased control 
3 Intelligent container for transporting organic 
samples 
Increased efficiency for laboratories due to automated 
process. Reduced number of ruined samples in 
transport due to improved safety. 
4 Angiogenesis inhibitor, which starves 
tumours by cutting off their blood supply 
More efficient treatment leading to improved patient 
satisfaction. 
5 Tele medicine solution Provision of distributed healthcare in remote areas at a 
reduced cost. 
6 Catheter with impregnated anti-microbial 
protection 
Catheter can be in place for prolonged times, 
rendering fewer infections, reducing number of 
catheters that needs to be used. 
Table 3.  Description of the six cases. 
 
Case 1.The firm was established 2007. The innovation project concerned a cloud-based IT 
system for assisting health care professionals dealing with patients suffering from multiple 
sclerosis (MS). Technical development started 2011. The aim of the system was to provide 
relevant information faster that would facilitate and speed up doctors’ decisions. A central 
feature of the design was usability, for instance, the system was set up to avoid double 
entering of data. The system also included some analytical services enabling comparison 
between the individual patient and non-personal data on other patients stored in the system’s 
data-base. During 2013, the firm scheduled to implement and test their technology at five 
major hospitals on their domestic market. Subsequently the firm envisaged to identify and 
exploit international markets. 
 
Case 2.This case consisted of a product that relied on decades of research on diabetes 
conducted by a research institute. The system was designed to allow monitoring and took into 
consideration factors that influence blood sugar levels, ultimately resulting in an increased 
personalization of diabetes treatment. The aim is to be able to better control diabetes, enabling 
patients to live more ‘normal’ lives and save a lot of the emergency procedures associated 
with lack of or failing diabetes control. The foreseen subsequent development step for the 
system was a portable service, which would reduce the need for the patients to visit treatment 
centers. A test version of the system is in operation. It is envisaged to diffuse the system, 
initially by gaining acceptance from clinicians on the domestic market, and subsequently to 
exploit international markets. 
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Case 3.The firm was established in 2006 and worked with software development for 
automated logistics solutions many times as a sub supplier to larger companies. The project 
considered here concerns the development of an intelligent transport box used for transport of 
organic samples to and from laboratories. Over the duration of the Healthport project the 
product was not finished or ready for actual trials. The developers envisaged that the transport 
box would increase efficiency at laboratories, because of the higher level of automation that 
would enable safer transport of samples and therefore reduce the risk that samples are ruined 
during transport. 
 
Case 4.This case concerned a commercial project (i.e. on organisation not established as a 
firm) administrated by a holding company in turn owned by a university. The project also 
benefited from close collaboration with a research firm. The firm who owned the project was 
established in 2011. The idea was based on more than 10 years of research in this field. The 
firm was transnational in the sense that the owners come from two different countries. The 
research was mainly conducted in one of the countries, while the management and 
commercial operations were based in the other. The product under development was an 
angiogenesis inhibitor, a drug designed to starve tumors by cutting off blood supply. Expected 
benefits would be a more efficient treatment and better patient satisfaction. The drug had gone 
through initial studies and demonstrated positive effects, and the project was therefore 
perceived as very promising.   
 
Case 5. Established in 2004, the firm worked with IT infrastructure and telemedicine. The 
firm had already introduced some products on their domestic market. As the firm perceived 
their home market too small it had begun to explore international markets with products 
already commercialized in their home country. The product portfolio ranged between 
products that patients were able to use on their own to services where a unit, such as a bus, 
was taken to the patients in remote areas. There were also products enabling communication 
between physicians. More products and services that extend the current services are in 
development. The main objective was to get the patient a better and faster service, which is 
currently either denied them, or at best is very expensive. In this manner, the patient will 
either be in contact with health care personnel over an IT solution, or basic health care 
services are taken to patients in mobile units, and the net result will be a better service at a 
cheaper price. The solutions are relevant in all countries where part of the population live in 
remote areas of the country. 
 
Case 6. The firm was founded in 2006 working initially with service provision in the life 
science industry. The firm’s focus has shifted towards getting a first successful product on the 
market. The innovation considered here concerns the development of a catheter with 
impregnated anti-microbial protection. The problem with existing catheter coatings is that 
they are fragile and short lived. The novelty of the catheter in question is that it uses an 
impregnated anti-microbial protection, based on impregnation of active components. This 
creates a drug depot and a transport route to the surface of the catheter that allows for a self-
regenerative surface. This means that the catheter can be in place for a prolonged period of 
time, which in turn reduces the number of catheters that need to be used. The solution also 
renders fewer infections. 
 
6.3. Barriers perceived by the firms 
 
Five main barriers were identified by the firms. These are discussed in the following. 
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Encountering regulations 
 
Case 1, which dealt with an IT solution handling patient data, reported perceived challenges 
in relations to the integrity regulations. In order to market the system on the domestic market, 
the firm had to interact with the national health authorities and the agency regulating 
management of personal data in order to be able to prove compliance with what the firm 
perceived as a very strict law. For case 4, concerning the development of an	angiogenesis	
inhibitor, this meant the rules and regulations necessary to comply with in connection with 
test and trials. The firm perceived that the amount of regulations made it difficult and 
expensive for a project to get to the latter stages of trials, and that this discourages a lot of 
potential successful projects from trying altogether. It was suggested that the rules could be 
softened without patient safety being at risk. Case 5, which involved tele-medicine solutions, 
also demonstrate similar viewpoints regarding strict regulatory guidelines: like case 1, the 
firm perceived data protection rules as a barrier to the ambition to integrate data from 
different countries. Another legal challenge was whether the products offered should be 
considered as software technology or a medical device, as this decision determines which 
laws applies. The case also reported about legal uncertainty regarding less known foreign 
markets.	
 
Different types of market barriers 
 
For the firm in case 2, one important barrier concerned what might be labelled diffusion 
barriers. Due to the setup of the particular health-system, the company had to convince both 
responsible physicians and patients about the benefits of the innovation. Barriers identified by 
the firm studied in case 1 concerned their ambition to exploit international markets. The firm 
reported a need to gather information to secure that the right markets were targeted. Another 
barrier related to “national pride”, i.e. the tendency to favor solutions developed by a 
domestic firm rather than a foreign firm. The firm in case 2 perceived it as hard to bring the 
innovation to market and to adapt the system to different health systems in different countries. 
Also, case 5 reported challenges due to differences in regulations across different 
international markets. A particular product-specific issue concerned the use of the solutions in 
a cross-border setting, requiring patient data to cross national borders.  
 
Negotiating oligarchical markets 
 
Case 1 reported a technical challenge related to integrating the new system with existing 
technology supplied by incumbent firms. Although the situation appears to be changing, what 
for this firm has been an oligarchical domestic market has in the past prevented entries of new 
suppliers of health-tech. A similar view was found also in case 3, which reflects a concern 
regarding the chances of a small firm to compete with larger firms. The firm perceived the 
tendency that larger firms “block out” smaller firms from the market as a significant barrier.  
 
Funding 
 
The project in case 1 received funding from a national innovation agency. The process of 
obtaining funding meant engaging in activities that for the firm, in retrospect, appear as side 
projects not central to the development of the innovation per se. After funding was secured, 
the focus shifted to making the system work. The funding from the national innovation 
agency was perceived as a critical success factor for the newly started firm, which did not 
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have any other references. The fact that the firm received funding was perceived as a way of 
legitimising the firm in the market. One challenge reported by the firm in case 4 was to find a 
major investor that could finance the further development of the drug. Hitherto it had been 
fairly easy to get access to smaller amounts of money, below 10.000€. There was some 
funding available in one of the countries available primarily for domestic firms. The fact that 
the firm was based in two countries excluded this opportunity for funding that would have 
been available had the firm been established as a completely domestic firm in that country. 
The firm managed to get funding from the innovation support agencies in the other country. 
The firm reported, however, allocating funding of magnitudes between 50.000€ or 100.000€, 
perceived as necessary for the further development, was very difficult to fulfill.  
 
Interaction with public customers 
 
The main challenges reported by the firm in Case 2 concerned getting the product on the 
market, which was a matter determined by how the health care was financed. In that country, 
insurance companies are the main funding source of health care, and patients and doctors 
expect insurance companies to pay for a service of the kind provided by the firm. This means 
that doctors have to be convinced of the relevance of the system. This is potentially difficult 
because it means that doctors are not solely in charge of the diagnosis and treatment of the 
patient. For the firm, it was perceived an advantage that they were part of a recognized 
organization with long experience in diabetes, which raises credibility amongst peers and 
make it more likely to be accepted by the doctors. 
 
An important issue in Case 3 was that the firm lacked understanding of how the public sector 
is organized and what perhaps could be labelled cultural aspects necessary to identify 
business opportunities; i.e. issues such as relational and political elements at work inside the 
health care organizations; how the decision making process works and who influences this 
process. For Case 4, on the other hand, the firm did not perceive interaction as problematic. 
They felt that their location in a business park connected to a hospital played an important 
role to facilitate the interaction. Case 6 reported an interesting work-around solution of 
problems potentially encountered on European markets. The firm made the decision to focus 
on the US market because of legal constraints imposed on health providers to deal with 
bacterial related illness and epidemics at hospitals. According to the firm, this is not the case 
in other countries. The perception was reported that in the US, they generally think in 
socioeconomics and benefits on a more holistic and societal level when looking at acquiring 
innovative products. This strengthens the business case for products that can achieve those 
goals better than existing products. 
 
 
6.4 Conclusions from the cases 
 
An analysis of the interviews reveals an array of problems and issues that are somewhat 
dependent on the specific case, such as securing venture capital, uncertainty regarding 
regulations, how to adequately choose a business model, uncertainty regarding foreign 
markets, issues on validation studies and finding relevant partners. Concerning IPR, the firms 
engaged in innovation in the medical sciences (cases 2, 4, 6) were about to file patents and/or 
already had secured patents protecting the underlying technology. Firms drawing on ICT 
(cases 1, 3, 5), did not find this a central issue, although one of these firms as a result of the 
interaction with the project considered to look into the possibilities of patenting 
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For most cases public procurement was not a central issue. It is noteworthy that the firms in 
Case 1, Case 2, Case 4 and Case 6 did not report any experience as a contract owner awarded 
through a public tender process. In Case 3 the firm reported negative perceptions of public 
procurement, even if the firm (similar to Cases 1 and 2) had no previous experiences as 
contract owners. However, the firms did have experience as a member of a consortium. 
Getting involved with a consortium was also the preferred strategy for future engagements as 
a supplier to public agencies. The only firm that reported having experience from acting as a 
contractor in public procurement was the one included in Case 5. They also stated that they 
have the necessary competences to participate in public procurement. 
 
For the six cases presented here some tentative conclusions can be made: most of the issues 
encountered and perceived as barriers for innovation were not directly linked to the domain of 
public procurement. One exception concerns the challenge associated with SME’s competing 
with incumbent firms on oligarchical markets. There is always a risk that an award decision in 
favour of a certain standard or technological trajectory will work to exclude any emerging 
alternatives. It is beyond the scope of this paper to discuss how to balance the need for 
exploiting the benefits from standards dictated by dominant suppliers against excluding 
competitive alternatives. For the present discussion, it suffices to note that this problem is 
probably not solved by a generic SME policy, but rather, innovation policy leading to 
management practices that affect how contracts are set-up, and the extent to which these 
moderate the negative effects from dominating suppliers in situations which would otherwise 
impede innovation.  
 
These conclusions have implications for the general emphasis on involving SME’s in public 
procurement seen in recent policy making. At least for firms similar to the ones included here, 
it appears unlikely that generic efforts to increase SME involvement in public procurement 
will be able to negotiate the barriers to commercialisation that these types of innovative firms 
encounter.  
 
7. Discussion 
 
At the first glance, using public procurement of innovation policies that target SME’s 
perceived as an innovative appears appealing. However, this paper presents evidence that 
raises doubt about the extent to which a generic approach would actually increase and/or 
enable innovation. Following the literature discussed here, there are certainly barriers for 
SME participation in public procurement. Some unsettled issues remain: whether or not 
barriers should be dealt with with any particular firm category in mind, or if this should be 
done in consideration for any potential bidder. Any divergence from a competitive tender 
process, for the sake of policy, might cause less rational contract award decisions. This paper 
scrutinizes statistics on SME involvement in public procurement, which establish that the 
share of SME’s involvement in public procurement is lower than would be expected if the 
importance of SME’s for the economy as a whole is taken into account. However, the 
available data only point towards tentative conclusions, and any there is no evidence that such 
‘fairness” is actually a sound expectation. The paper refers also to some studies that consider 
role of firm size in relation to innovation which render ambiguous outcomes. Although some 
of the studies drawn on were able to identify differences among specific sectors, the general 
claim that smaller firms would be more innovative than larger firms is not supported. Finally, 
the case study of  these six small, innovative health-tech firms reported here, suggest that 
most of the innovation barriers these firms encountered would not be solved by public 
procurement policy aimed at promoting SME involvement.  
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Even if innovative categories of SME’s could be identified and made distinct from those 
which are not, such distinction would not automatically determine which specific actions to 
take. Policy makers would still need to figure out what category of SME should become the 
target of public procurement of innovation policies. Among some options to consider would 
be identifying SMEs with previously-established track record of successful innovation; or 
those judged to have innovation potential, or potential as a job-creator, or any other criteria 
(c.f. Gibb, 2000).  What goes for any policy measure is however the requirement of 
additionality, i.e. that the envisaged effects of a policy measure would not materialise unless 
the measure were implemented. Following that view, the application of public procurement of 
innovation would be justifiable if it could negotiate a situation where the market is not 
otherwise able to deliver innovation. Public procurement of innovation seen as a process 
requiring more resources than off-the-shelf procurement, evoked in a situation where the 
market is already capable of supplying innovation or suffering from problems cannot be 
resolved by public procurement policies, could be seen as a waste of public resources. 
Formulated in a more generic way, one could wonder whether any category of firm should be 
promoted because it is already innovative, or should it be promoted rather because it is 
underperforming in terms of innovation?  
 
It should perhaps be noted that this paper neither asserts that SME involvement in public 
procurement is a bad thing, nor claims that SME’s should not be able to contribute with 
innovative solutions. For the sake of innovation promotion, the SME category, i.e. the 
bundling together of all kinds of firms, seems less useful as a target group. One could argue 
that the solution is to be found on more endogenous levels (Rolfstam, 2013). If public 
procurers and technology managers within the public health sector develop innovation-
friendly practices that promote innovative firms regardless of size, this might help to connect 
to other innovative SMEs. Such an approach would be a way of ‘transposing’ policy 
formulated on the EU level, to the level of hospital procurement decision makers – a process 
that moves from policies aimed at promoting SME’s in general, to innovation policies 
implemented in endogenous practice that promote innovative firms. 
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